Eton Pharmaceuticals (ETON) news

Eton Pharmaceuticals shares rise 41% after Q2 profit beat

Eton Pharmaceuticals (Nasdaq: ETON) reported second-quarter 2026 financial results that significantly exceeded expectations, driving a 41% stock price increase . The company posted a 99% year-over-year revenue increase , driven by strong performance across its rare disease portfolio, including the…

Eton Pharmaceuticals Inc: Company now expects 2026 revenues to exceed $145 mln

Eton Pharmaceuticals, Inc. (ETON) has raised its full-year 2026 revenue guidance, now expecting to exceed $120 million , up from its previous forecast of $110 million. This update follows strong first-quarter performance, with a 73% increase compared to Q1 2025 . The growth was driven by robust…

Eton Pharmaceuticals increases from prior guidance of over $120M

First Tracks Biopharmaceuticals, Inc.: H.C. Wainwright raises target price to $57 from $44

First Tracks Biopharmaceuticals, Inc. (TRAX) has seen its 12-month price target raised by analysts, reflecting growing optimism about its future performance. According to the latest consensus from eight analysts, the average price target for the company’s stock has increased to $60.50 from $53.25,…

Eton Pharmaceuticals Inc: H.C. Wainwright raises target price to $65 from $57

H.C. Wainwright has raised its price target for Eton Pharmaceuticals (NASDAQ: ETON) to $65 from $57, maintaining its Buy rating on the stock. The adjustment reflects the firm’s confidence in the company’s strong revenue performance and growth trajectory. Eton’s first-quarter 2026 results showed…